Insulet/PODD

$192.21

0.62%
-
1D1W1MYTD1YMAX

About Insulet

Insulet Corporation is primarily engaged in the development, manufacture and sale of its Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) that the user fills with insulin and wears directly on the body for up to three days at a time, which delivers personalized doses of insulin, and the Personal Diabetes Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with the user's personalized insulin-delivery instructions and wirelessly monitors the Pod's operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta.
Ticker
PODD
Sector
Healthcare
Trading on
NASDAQ
Industry
Medical Equipment & Supplies
CEO
James Hollingshead
Employees
2,600
Headquarters
Acton, United States

Insulet Metrics

BasicAdvanced
$13.34B
Market cap
114.30
P/E ratio
$1.67
EPS
1.02
Beta
-
Dividend rate

What the Analysts think about Insulet

Analyst Ratings

Majority rating from 22 analysts.
Buy

Price Targets

Average projection from 19 analysts.
23.01% upside
High $270.00
Low $190.00
$192.21
Current price
$236.44
Average price target

Insulet Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
11.99% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$432.7M
9.13%
Net income
$51.9M
90.11%
Profit margin
11.99%
74.27%

Insulet Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 76.54%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
$0.49
$0.23
$0.38
$0.71
-
Expected
$0.21
$0.11
$0.26
$0.40
$0.66
Surprise
130.62%
115.74%
44.52%
76.54%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Insulet stock

Buy or sell Insulet stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing